Corvus Pharmaceuticals, Inc.
NASDAQ:CRVSBiotechnology
-$0.19 today
- Market cap
- $857.87M
- Beta
- 0.84
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.49
Volume 0.93M
Average 1.49M
Returns on capital
Corvus Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-25.0%
avg -46.6%
ROIC
-69.1%
avg -52.8%
ROA
-21.5%
avg -44.6%
Analysis
ROA is currently the strongest return metric at -21.5% versus its period average of -44.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Leiv Lea | Chief Financial Officer | USD 411.95K | 72 | 400.00K | 0.48% |
William Benton Jones | Senior Vice President of Pharmaceutical Development | USD 366.12K | 60 | 400.00K | 0.48% |
Peter A. Thompson FACP | Co-Founder & Independent Director | USD 47K | 66 | — | — |
Richard A. Miller | Co-Founder, President, Chief Executive Officer & Chairman of the Board | USD 42.57K | 75 | — | — |
Jeffrey S. Arcara | Senior Vice President & Chief Business Officer | — | 57 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Dec 4, 2025.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
7
$384,164.25
Sells
0
$0.00
Net Transaction Value
+$384,164.25
Net buying
Most Active
Arcara Jeffrey
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 13, 26Nov 13, 2026 | Arcara Jeffrey Direct | Buy | $5.4K$5,354.35 |
| Nov 13, 26Nov 13, 2026 | Arcara Jeffrey Direct | Buy | $5.2K$5,216.11 |
| Nov 12, 26Nov 12, 2026 | Arcara Jeffrey Direct | Buy | $5.5K$5,524.16 |
| Nov 11, 26Nov 11, 2026 | Arcara Jeffrey Direct | Buy | $34.4K$34,380.60 |
| Jun 11, 26Jun 11, 2026 | Moore David Scott Direct | Buy | $250.2K$250,235.72 |
| May 18, 26May 18, 2026 | MILLER RICHARD A MD Indirect | Buy | $23.2K$23,203.32 |
| May 18, 26May 18, 2026 | MILLER RICHARD A MD Indirect | Buy | $60.3K$60,250.00 |
Summary
Insiders reported 7 buys worth $384,164.25 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $384,164.25. Arcara Jeffrey was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Corvus Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about CRVS's management, answered from reported figures.
Who manages CRVS?
Corvus Pharmaceuticals, Inc. (CRVS) lists 5 active executives. The top listed executive is Peter A. Thompson FACP, Co-Founder & Independent Director.
Are CRVS insiders buying or selling?
Recent insider activity shows net buying of $5.14M.
Continue the stock analysis
Jump to another research area for this company.